MCID: SCK005
MIFTS: 48

Sickle Cell Disease malady

Categories: Genetic diseases (common), Immune diseases, Blood diseases

Aliases & Classifications for Sickle Cell Disease

About this section

Aliases & Descriptions for Sickle Cell Disease:

Name: Sickle Cell Disease 23 24 25 50 2
Sickling Disorder Due to Hemoglobin S 25
Sickle Cell Disorders 25
Hemoglobin S Disease 25
 
Anemia, Sickle Cell 68
Hbs Disease 25
Scd 25

Classifications:



External Ids:

ICD1030 D57

Summaries for Sickle Cell Disease

About this section
Genetics Home Reference:25 Sickle cell disease is a group of disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disorder have atypical hemoglobin molecules called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape.

MalaCards based summary: Sickle Cell Disease, also known as sickling disorder due to hemoglobin s, is related to malaria and splenic infarction, and has symptoms including chest pain An important gene associated with Sickle Cell Disease is HBB (Hemoglobin Subunit Beta), and among its related pathways are African trypanosomiasis and Factors involved in megakaryocyte development and platelet production. The drug sodium phenylbutyrate has been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and endothelial, and related mouse phenotype Increased shRNA abundance.

Wikipedia:71 Sickle-cell disease (SCD) is a group of blood disorders typically inherited from a person\'s parents.... more...

GeneReviews for NBK1377

Related Diseases for Sickle Cell Disease

About this section

Diseases related to Sickle Cell Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 207)
idRelated DiseaseScoreTop Affiliating Genes
1malaria30.9EPO, G6PD, HBA2, HBB, SELP, VCAM1
2splenic infarction30.4EPO, HBB
3sickle cell anemia30.0BCL11A, EPO, HBA2, HBB, HBD, HBG1
4pyruvate kinase deficiency29.1EPO, G6PD, HBA2, HBG2
5hereditary persistence of fetal hemoglobin-sickle cell disease syndrome12.0
6sickle cell disease associated with an other hemoglobin anomaly11.9
7acute chest syndrome11.4
8corneal dystrophy, schnyder type11.4
9superior semicircular canal dehiscence syndrome11.4
10hemoglobinopathy11.3
11sickle beta thalassemia11.2
12obesity11.0
13abdominal obesity-metabolic syndrome 111.0
14diabetes mellitus, noninsulin-dependent10.9
15reye syndrome10.9
16spondylocheirodysplasia, ehlers-danlos syndrome-like10.9
17moyamoya disease10.8
18phthisical cornea10.6BCAM, HBB
19bartholin's gland adenoma10.6HBB, HBS1L
20parkinson disease type 310.5HBA2, HBB
21heinz body anemia10.5HBA2, HBB
22gaba-transaminase deficiency10.5HBA2, HBB
23dic in newborn10.4EPO, HBA2
24suppurative otitis media10.4EPO, HBA2
25thalassemia10.3
26priapism10.3
27thrombocytopenia due to platelet alloimmunization10.3HBB, VCAM1
28tenosynovial giant cell tumor10.3SELP, VCAM1
29splenic sequestration10.3
30wernicke encephalopathy10.3G6PD, UGT1A1
31preeclampsia/eclampsia 410.3G6PD, HBA2, HBB
32histoplasmosis10.3PGF, SELP
33intracranial primitive neuroectodermal tumor10.3SELP, VCAM1
34thbd-related atypical hemolytic-uremic syndrome10.2HBB, HBG2
35peripheral vascular disease10.2G6PD, HBG2
36larynx sarcoma10.2G6PD, HBB, UGT1A1
37pulmonary hypertension10.2
38arteriolosclerosis10.2SELP, VCAM1
39endotheliitis10.2
40mosaic genome-wide paternal uniparental disomy10.1HBB, HBD
41internuclear ophthalmoplegia10.1HBB, HBD
42pneumonia caused by pseudomonas aeruginosa infection10.1HBB, HBG1, HBG2
43avascular necrosis of the femoral head10.1
44gemistocytic astrocytoma10.1EPO, SELP, VCAM1
45intracranial cavernous angioma10.1HBB, HBD
46vulvar proximal-type epithelioid sarcoma10.1HBB, HBD
47cerebritis10.1
48uterine inflammatory disease10.1HBB, HBD
49congenital nonspherocytic hemolytic anemia10.1HBB, HBD
50asthma10.1

Graphical network of the top 20 diseases related to Sickle Cell Disease:



Diseases related to sickle cell disease

Symptoms & Phenotypes for Sickle Cell Disease

About this section

UMLS symptoms related to Sickle Cell Disease:


chest pain

GenomeRNAi Phenotypes related to Sickle Cell Disease according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00327-A8.8EPO, G6PD, HBD, HBG2

Drugs & Therapeutics for Sickle Cell Disease

About this section

Drugs for Sickle Cell Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 383)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
RibavirinapprovedPhase 498436791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
2
Deferoxamineapproved, investigationalPhase 4, Phase 2, Phase 34570-51-92973
Synonyms:
DF B
DFO
DFOA
DFOM
Deferoxamide B
Deferoxamin
Deferoxamina
 
Deferoxamine B
Deferoxaminum
Deferrioxamine
Deferrioxamine B
Deferrioxamine b
Desferrioxamine
Desferrioxamine B
Déferoxamine
N-Benzoylferrioxamine B
3
Deferasiroxapproved, investigationalPhase 4, Phase 3, Phase 289201530-41-85493381
Synonyms:
Deferasiroxum
Deferasiroxum [inn-latin]
 
Exjade
ICL 670
ICL 670a
deferasirox
4
HydroxyureaapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1215127-07-13657
Synonyms:
1-HYDROXYUREA
127-07-1
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
BRN 1741548
BSPBio_002164
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
C07044
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
Carbamohydroxamic Acid
Carbamohydroxamic acid
Carbamohydroximic Acid
Carbamohydroximic acid
Carbamohydroxyamic Acid
Carbamohydroxyamic acid
Carbamoyl Oxime
Carbamoyl oxime
Carbamyl Hydroxamate
Carbamyl hydroxamate
Carrbamoyl Oxime
D00341
D006918
DB01005
DRG-0253
DivK1c_000556
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
HYDREA (TN)
HYDROXY-UREA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
Hydrea
Hydrea (TM)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
Hydroxyurea
Hydroxyurea (D4)
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
 
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [DCIT]
Idrossicarbamide [Dcit]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
LS-709
Litaler
Litalir
Lopac-H-8627
Lopac0_000596
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
NCI C04831
NCI-C04831
NCI60_002773
NCIMech_000139
NHY
NINDS_000556
NSC 32065
NSC32065
Onco-Carbide
Onco-carbide
Oncocarbide
Oxyurea
S-phase/G-1 interface inhibitor
S1896_Selleck
SK 22591
SMR000059149
SPBio_000247
SPECTRUM1500344
SQ 1089
SQ-1089
Siklos
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
Spectrum_000909
Sterile Urea
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
carbamide oxide
hydroxyaminomethanamide
hydroxyurea
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
tetratogen: inhibits ribonucleoside diphosphate reductase
5
Peginterferon alfa-2bapprovedPhase 430899210-65-8, 215647-85-1
Synonyms:
215647-85-1
D02748
PEG-Intron
PegIntron
 
Peginterferon alfa-2b
Peginterferon alfa-2b (INN)
Peginterferon alfa-2b (generical recombination)
Peginterferon alfa-2b (generical recombination) (JAN)
Pegintron (TN)
Unitron PEG
6
Peginterferon alfa-2aapproved, investigationalPhase 4563198153-51-45360545
Synonyms:
198153-51-4
D02747
Pegasys
 
Pegasys (TN)
Peginterferon alfa-2a
Peginterferon alfa-2a (USAN/INN)
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
7
DeferiproneapprovedPhase 4, Phase 2, Phase 3, Phase 15730652-11-02972
Synonyms:
1,2-Dimethyl-3-hydroxypyrid-4-one
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
APO-066
CP-20
DN-180-01-AF
Deferipron
 
Deferiprona
Deferiproni
Deferipronum
Deferypron
Dimethylhydroxypyridone
Défériprone
Ferriprox
PL-1
8
IronapprovedPhase 4, Phase 3, Phase 2, Phase 111237439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
9
Fentanylapproved, illicit, investigational, vet_approvedPhase 4, Phase 2773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
10
Guaifenesinapproved, vet_approvedPhase 4, Phase 1, Phase 261693-14-13516
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
Amonidren
Amonidrin
Aresol
Benylin-E
Bronchol
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
 
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphesin
Hustosil
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
Pneumomist
Propanosedyl
Reduton
Robitussin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
guaiphenesin
p-Cresyl acetate
11
Ketamineapproved, vet_approvedPhase 4, Phase 3, Phase 25286740-88-13821
Synonyms:
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(-)-Ketamine
(S)-(-)-Ketamine
(S)-Ketamine
(±)-ketamine
100477-72-3
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Calypsol
Cetamina
Cetamina [INN-Spanish]
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
 
DL-ketamine
DivK1c_000217
EINECS 229-804-1
Esketamine
Green
IDI1_000217
KBio1_000217
KETAMINE
KETAMINE HCL
Ketaject
Ketalar
Ketalar base
Ketamina
Ketamine (INN)
Ketamine Base
Ketamine HCL
Ketamine [INN:BAN]
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketoject
Ketolar
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
Special k
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
dl-Ketamine
ketamine
l-Ketamine
12
Morphineapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 296057-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
13
Codeineapproved, illicitPhase 4, Phase 1, Phase 27476-57-35284371
Synonyms:
(-)-Codeine
(5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
(5α,6α)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
(6alpha,13alpha)-3-methoxy-17-methyl-7,8-didehydro-4,5-epoxymorphinan-6-ol
(−)-Codeine
3-Methylmorphin
3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol
3-methylmorphine
3-o-methylmorphine monohydrate
41444-62-6 (PO4)
7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methylmorphinan-6-alpha-ol
7,8-didehydro-4,5-ep oxy-3-methoxy-17-methylmorphinan-6-ol
7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-(5alpha, 6alpha)-morphinan 6-ol
7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol
7,8-didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol
76-57-3
AC-11114
AC1Q4DTD
Actacode
Ardinex
C06174
C1653_FLUKA
C1653_SIGMA
C5901_FLUKA
C5901_SIGMA
CCRIS 7555
CHEBI:16714
CHEMBL485
CID5284371
CODEINE (SEE ALSO: CODEINE PHOSPHATE (CAS 52-28-8))
CODEINE BASE
Calcidrine
Codalgin Forte Codate
Codein
Codeine
Codeine (anhydrous)
Codeine [BAN]
Codeine anhydrous
Codeine solution
 
Codeinum
Codeína
Codicept
Coducept
Codéine
DB00318
EINECS 200-969-1
HSDB 3043
Isocodeine
L-Codeine
LS-1695
Methylmorphine
MolPort-002-506-913
Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5-alpha,6-alpha)- (9CI)
Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)- (9CI)
Morphinan-6alpha-ol, 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methyl- (8CI)
Morphine 3-methyl ether
Morphine monomethyl ether
Morphine-3-methyl ester
Morphine-3-methyl ether
N-Methylmorphine
N-methyl norcodine
N-methylnorcodeine
Norcodeine, N-Methyl
Norcodeine, N-methyl
Norcodine, N-Methyl
Norcodine, N-methyl
Novahistine DH
O(3)-methylmorphine
O3-Methylmorphine
Robitussin AC
STOCK1N-42851
codeina
codeine
codeinum
l-Codeine
metilmorfina
morphine 3-methyl ether
morphine monomethy l ether
morphine monomethyl ether
morphine-3-methyl ether
nchembio.317-comp2
14
Hydromorphoneapproved, illicitPhase 4, Phase 3, Phase 2176466-99-95284570
Synonyms:
(-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one
(-)-Hydromorphone
(5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one
18145-12-5
3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one
4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone
41376-02-7
466-99-9
6-Deoxy-7,8-dihydro-6-oxomorphine
7,8-Dihydromorphinone
C07042
CHEBI:5790
CHEMBL398707
CID5284570
D08047
DB00327
DEA No. 9150
DiMo
Dihydromorfinon
Dihydromorfinon [Czech]
Dihydromorphinone
Dilaudid
Dilaudid Oros
Dilaudid-hp
Dimorphone
 
EINECS 207-383-5
HSDB 3341
Hidromorfona
Hidromorfona [INN-Spanish]
Hydromorfona
Hydromorfona [Spanish]
Hydromorphon
Hydromorphone
Hydromorphone (INN)
Hydromorphone HCL
Hydromorphone [INN:BAN]
Hydromorphonum
Hydromorphonum [INN-Latin]
Idromorfone
Idromorfone [DCIT]
LS-187185
LS-92152
Laudacon
Laudicon
MolPort-004-285-951
Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl- (8CI)
NSC 19046
NSC19046
Novolaudon
UNII-Q812464R06
WLN: T B6566 B6/CO 4ABBC R BX FV HO PN GHT&&TTJ JQ P1
hydromorphone
15
IbuprofenapprovedPhase 4, Phase 250115687-27-13672
Synonyms:
(+-)-2-(P-Isobutylphenyl)propionic acid
(+-)-Ibuprofen
(+-)-P-Isobutylhydratropic acid
(+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid
(4-Isobutylphenyl)-alpha-methylacetic acid
(RS)-ibuprofen
139466-08-3
15687-27-1
2-(4-Isobutylphenyl)propanoic acid
4-Isobutylhydratropic acid
58560-75-1
AC-11312
AC1L1GGE
AC1Q1P84
AC1Q1P85
ACHES-N-PAIN
ARONIS23835
Act-3
Actiprofen
Adex 200
Adran
Advil
Advil (TN)
Advil Liqui-Gels
Ak+C2278tren
Alaxan
Algofen
Am-Fam 400
Amelior
Amersol
Amibufen
Anafen
Anco
Andran
Anflagen
Antagil
Antalfene
Antarene
Antiflam
Apo-Ibuprofen
Apsifen
Apsifen-F
Artofen
Artril
Artril 300
BB_SC-1358
BIDD:GT0050
BRN 2049713
Balkaprofen
Betaprofen
Bloom
Bluton
Brofen
Brufanic
Brufen
Brufen 400
Bruflam
Brufort
Buburone
Bufeno
Bufigen
Bukrefen
Bupron
Buracaps
Burana
Butylenin
C01588
C13H18O2
CCRIS 3223
CHEBI:5855
CHEMBL521
CID3672
CPD000058184
Cap-Profen
Carol
Cesra
Children's Advil
Children's Elixsure
Children's Ibuprofen
Children's Motrin
Citalgan
Cobo
Codral
Combiflam
Cunil
D00126
D007052
DB01050
DOLO PUREN
Daiprophen
Dalsy
Dansida
Deep Relief
Dentigoa
Dibufen
Dignoflex
Dolgin
Dolgirid
Dolgit
Dolibu
Dolmaral
Dolo-Dolgit
Dolo-dolgit
Dolocyl
Dolofen
Dolofen-F
Dolofin
Dolofort
Dologel
Dolomax
Doloren
Dolormin
Doltibil
Dolven
Donjust B
Dorival
Drin
Duafen
Duobrus
Dura-Ibu
Duralbuprofen
Dysdolen
EU-0100691
Easifon
Ebufac
Emflam
Emflam-200
Emodin
Epobron
Eputex
Ergix
Esprenit
Exneural
Faspic
Femadon
Femafen
Femapirin
Femidol
Fenbid
Fenbid Spansule
Fendol
Fenspan
Fibraflex
Gelufene
Gofen
Grefen
Gynofug
HMS1920F15
HMS2089P05
HMS2091N03
HMS502M09
HSDB 3099
Haltran
I 4883
I01-7039
I0415
I4883_SIGMA
I7905_SIAL
IB-100
IDI1_000887
IP 82
IP-82
IP82
Ibol
Ibren
Ibu
Ibu-Attritin
Ibu-Slo
Ibu-Tab
Ibu-Tab 200
Ibu-attritin
Ibu-slo
Ibu-slow
Ibubest
Ibubeta
Ibucasen
Ibudol
 
Ibudolor
Ibufen
Ibuflamar
Ibufug
Ibugel
Ibugen
Ibugesic
Ibuhexal
Ibulagic
Ibular
Ibulav
Ibuleve
Ibulgan
Ibumed
Ibumerck
Ibumetin
Ibupirac
Ibuprin
Ibuprocin
Ibuprofen
Ibuprofene
Ibuprofeno
Ibuprofenum
Ibuprohm
Ibuprophen
Ibusal
Ibutid
Ifen
Inabrin
Inflam
Inoven
Ipren
Irfen
Isodol
Jenaprofen
Junifen
Junior Strength Advil
Junior Strength Ibuprofen
Junior Strength Motrin
KBio1_000887
KBio2_001329
KBio2_003897
KBio2_006465
KBio3_001390
Kesan
Kratalgin
LS-7454
Lamidon
Lebrufen
Librofem
Lidifen
Liptan
Lopane
MLS000069733
MLS001146965
Malafene
Manypren
Medipren
Melfen
Mensoton
Midol
Midol 200
Moment
Motrin
Motrin (TN)
Motrin IB
Mynosedin
NCI60_002065
NINDS_000887
NSC 256857
NSC256857
Nagifen-D
Napacetin
Narfen
Neo-Helvagit
Neo-Mindol
NeoProfen
Neobrufen
Nerofen
Noalgil
Nobafon
Nobfelon
Nobfen
Nobgen
Noritis
Norton
Novadol
Novo-Profen
Novogent
Novogent N
Novoprofen
Nuprilan
Nuprin
Nurofen
Optifen
Opturem
Oralfene
Ostarin
Ostofen
Ozonol
P-Isobutylhydratropic Acid
Paduden
Panafen
Pantrop
Para-Isobutylhydratropic Acid
Paxofen
Pedia-Profen
PediaProfen
Pediaprofen
Pediatric Advil
Perofen
Proartinal
Profen
Proflex
Provon
Quadrax
R.D. 13621
RD 13621
Rafen
Ranofen
Rebugen
Relcofen
Rhinadvil
Rofen
Roidenin
Rufen
Rufin
Rupan
SAM002264619
SMR000058184
SPBio_000178
STK177358
Sadefen
Salivia
Salprofen
Seclodin
Sednafen
Seklodin
Seskafen
Siyafen
Solpaflex
Solufen
Stelar
Sugafen
Suprafen
Suspren
Syntofene
TL8001184
Tab-Profen
Tabalon
Tabalon 400
Tatanal
Tempil
Tofen
Togal N
Tonal
Trendar
U 18573
U-18,573
U-18573
UCB 79171
Unipron
Upfen
Uprofen
Urem
VUFB 9649
Zafen
Zofen
alpha-(4-Isobutylphenyl)propionate
alpha-(4-Isobutylphenyl)propionic acid
alpha-(P-Isobutylphenyl)propionic acid
alpha-p-Isobutylphenylpropionate
alpha-p-Isobutylphenylpropionic acid
ibuprofen
p-Isobutyl-2-phenylpropionate
p-Isobutyl-2-phenylpropionic acid
p-Isobutylhydratropate
p-Isobutylhydratropic acid
16
DesogestrelapprovedPhase 48054024-22-540973
Synonyms:
(17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol
13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol
13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol
17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
54024-22-5
AC-308
AC1L24T4
AC1Q282A
C07629
C22H30O
CHEBI:4453
CHEMBL1533
CID40973
Cerazette
D017135
D02367
 
DB00304
DESOGESTREL
Desogestrel (USAN/INN)
Desogestrel [USAN:BAN:INN]
Desogestrelum
Desogestrelum [INN-Latin]
EINECS 258-929-4
HSDB 3593
LMST02030104
LS-62079
MolPort-003-846-424
NCGC00167449-01
ORG 2969
Org-2969
Org2969
Organon Brand of Desogestrel
UNII-81K9V7M3A3
ZINC04097416
alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17
desogen
17
Etonogestrelapproved, investigationalPhase 47754048-10-140976, 6917715
Synonyms:
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
17alpha-ethynyl-17beta-hydroxy-11-methylidene-18a-homo-estr-4-en-3-one
3-Ketodesogestrel
3-Oxodesogestrel
54048-10-1
AC1OCEK1
CHEBI:50777
CHEMBL1531
CID6917715
 
D04104
ETONOGESTREL
Etonogestrel (USAN/INN)
Etonogestrelum
Implanon
Implanon (TN)
MolPort-003-847-336
NCGC00168777-01
Org-3236
ZINC11680067
etonogestrelum
18
Heroinapproved, illicitPhase 4113561-27-35462328
Synonyms:
(5α,6α)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate (ester)
3,6-Diacetylmorphine
7,8-Dihydro-4,5-alpha-epoxy-17-methylmorphinan-3,6-alpha-diol diacetate
Diacetylmorphine
 
Diamorphine
O,O'-Diacetylmorphine
Smack
diacetylmorphine
diamorphine
19
KetorolacapprovedPhase 430474103-06-3, 66635-83-43826
Synonyms:
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-Ketorolac
(+-)-isomer
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC-545
AC1L1GSW
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
 
I14-2832
Ketoralac
Ketorolac
Ketorolac (INN)
Ketorolac Tromethamine
Ketorolac [INN:BAN]
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
Kétorolac
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
RS 37619
RS-37619
SBB067312
STL018674
Toradol (TN)
UNII-YZI5105V0L
ketorolac
rac-Ketorolac
20Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13868
21Iron Chelating AgentsPhase 4, Phase 3, Phase 2, Phase 1222
22Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 110355
23MicronutrientsPhase 4, Phase 3, Phase 2, Phase 15802
24Trace ElementsPhase 4, Phase 3, Phase 2, Phase 15802
25VaccinesPhase 4, Phase 3, Phase 26428
26Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 19732
27Interferon-alphaPhase 41139
28interferonsPhase 42137
29Calcium, DietaryPhase 4, Phase 2, Phase 3, Phase 15525
30Respiratory System AgentsPhase 4, Phase 3, Phase 2, Phase 14818
31AntimetabolitesPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 111774
32Chelating AgentsPhase 4, Phase 3, Phase 2, Phase 11365
33Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14855
34Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
35Phosphodiesterase InhibitorsPhase 4, Phase 2, Phase 11254
36Sildenafil CitratePhase 4, Phase 2, Phase 1323171599-83-0
37Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 16260
38NarcoticsPhase 4, Phase 3, Phase 1, Phase 23486
39Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 3, Phase 2, Phase 14295
40Cyclooxygenase InhibitorsPhase 4, Phase 1, Phase 22778
41Antitussive AgentsPhase 4, Phase 1, Phase 2520
42Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112767
43Chlorpheniramine, phenylpropanolamine drug combinationPhase 4, Phase 1, Phase 2616
44Heptavalent Pneumococcal Conjugate VaccinePhase 4, Phase 3, Phase 2454
45Phosphodiesterase 5 InhibitorsPhase 4, Phase 2, Phase 1571
46Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110627
47Vasodilator AgentsPhase 4, Phase 2, Phase 3, Phase 13438
48Central Nervous System DepressantsPhase 4, Phase 2, Phase 3, Phase 112806
49Analgesics, OpioidPhase 4, Phase 3, Phase 1, Phase 23091
50AnalgesicsPhase 4, Phase 3, Phase 2, Phase 111287

Interventional clinical trials:

(show top 50)    (show all 562)
idNameStatusNCT IDPhase
1Interferon and Ribavirin Treatment in Patients With HemoglobinopathiesUnknown statusNCT00887081Phase 4
2Comparing Acute Pain Management Protocols for Patients With Sickle Cell DiseaseCompletedNCT02222246Phase 4
3Future of Spermatogenesis in Men With Sickle Cell Disease Medically TreatedCompletedNCT01609192Phase 4
4Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)CompletedNCT02522104Phase 4
5Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive CrisisCompletedNCT01482091Phase 4
6Pilot Study for Patients With Poor Response to DeferasiroxCompletedNCT00749515Phase 4
7Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in SicklersCompletedNCT02434939Phase 4
8Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to FoodCompletedNCT00845871Phase 4
9Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasRecruitingNCT02041299Phase 4
10Contraception in Women With Sickle Cell DiseaseActive, not recruitingNCT02594462Phase 4
11Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea TreatmentEnrolling by invitationNCT02149537Phase 4
12Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasEnrolling by invitationNCT02443545Phase 4
13Mobile-Directly Observed Therapy on Adherence to HydroxyureaEnrolling by invitationNCT02844673Phase 4
14Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent TransfusionsNot yet recruitingNCT02731157Phase 4
15Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & MorphineTerminatedNCT00880373Phase 4
16Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell DiseaseTerminatedNCT00252122Phase 4
17Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell DiseaseTerminatedNCT00115336Phase 4
18Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.TerminatedNCT00368186Phase 4
19Assessment of Opioid Analgesia in Sickle CellWithdrawnNCT00513864Phase 4
20Endothelial Function in Patients With Sickle Cell Anemia Before and After SildenafilWithdrawnNCT00937144Phase 4
21Transfusion Alternatives Pre-Operatively in Sickle Cell Disease (TAPS)Unknown statusNCT00512577Phase 3
22Clinical Importance of Treating Iron Overload in Sickle Cell DiseaseUnknown statusNCT00981370Phase 3
23Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study)Unknown statusNCT00890396Phase 3
24Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron OverloadUnknown statusNCT01511848Phase 2, Phase 3
25Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell DiseaseCompletedNCT00560261Phase 3
26Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)CompletedNCT01737814Phase 3
27L-Arginine and Sickle Cell DiseaseCompletedNCT01142219Phase 3
28Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell DiseaseCompletedNCT00393250Phase 3
29N-Acetylcysteine in Patients With Sickle Cell DiseaseCompletedNCT01849016Phase 3
30Steroid Treatment for Sickle Cell Pain CrisisCompletedNCT00263562Phase 3
31A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemiaCompletedNCT01179217Phase 3
32Evaluation of Repeat Administration of Purified Poloxamer 188CompletedNCT02449616Phase 3
33Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell DiseaseCompletedNCT00918580Phase 3
34Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell DiseaseCompletedNCT00004408Phase 3
35Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell AnemiaCompletedNCT00399074Phase 3
36Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)CompletedNCT01411280Phase 3
37Intravenous Magnesium for Sickle Cell Vasoocclusive CrisisCompletedNCT01197417Phase 2, Phase 3
38Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)CompletedNCT00000586Phase 3
39Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell AnemiaCompletedNCT00006400Phase 3
40Penicillin Prophylaxis in Sickle Cell Disease (PROPS)CompletedNCT00000585Phase 3
41Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)CompletedNCT00748423Phase 2, Phase 3
42Stroke Prevention in Sickle Cell Anemia (STOP 1)CompletedNCT00000592Phase 3
43Silent Cerebral Infarct Transfusion Multi-Center Clinical TrialCompletedNCT00072761Phase 3
44Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell TraitCompletedNCT00005782Phase 3
45Stroke Prevention in Sickle Cell Anemia (STOP 2)CompletedNCT00006182Phase 3
46MAST - Magnesium for Sickle Cell Acute Crisis in ChildrenCompletedNCT00313963Phase 3
47Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3
48A Trial of Hydroxyurea in Spinal Muscular AtrophyCompletedNCT00485511Phase 2, Phase 3
49Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850ACompletedNCT01175083Phase 3
50A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadCompletedNCT00171821Phase 3

Search NIH Clinical Center for Sickle Cell Disease

Inferred drug relations via UMLS68/NDF-RT46:

Genetic Tests for Sickle Cell Disease

About this section

Genetic tests related to Sickle Cell Disease:

id Genetic test Affiliating Genes
1 Sickle Cell Disease24 HBB

Anatomical Context for Sickle Cell Disease

About this section

MalaCards organs/tissues related to Sickle Cell Disease:

36
Bone, Bone marrow, Endothelial, Kidney, Lung, Liver, Brain

Publications for Sickle Cell Disease

About this section

Articles related to Sickle Cell Disease:

(show top 50)    (show all 1246)
idTitleAuthorsYear
1
Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. (28092109)
2017
2
Acute vaso-occlusive crisis in patients with sickle cell disease. (28027139)
2017
3
Enhanced Long-Term Brain MRI Evaluation of Children with Sickle Cell Disease Following Hematopoietic Cell Transplantation. (28089760)
2017
4
Perceived Racial Bias and Health-Related Stigma Among Youth with Sickle Cell Disease. (28059954)
2017
5
Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Children with Sickle Cell Disease and Thalassemia: a Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. (28065838)
2017
6
Acute Pain in Adolescents and Young Adults with Sickle Cell Disease: Delayed and Increased Opioid Dosing Following Transition to Adult Care. (28066934)
2017
7
Risk Factors for 30-day Readmission in Adults with Sickle-Cell Disease. (28065771)
2017
8
Regulation of Active ICAM-4 on Normal and Sickle Cell Disease RBCs via AKAPs Is Revealed by AFM. (28076805)
2017
9
Hemoglobin-Based Blood Substitutes and the Treatment of Sickle Cell Disease: More Harm than Help? (28054978)
2017
10
Hydroxyurea treatment effect on children with sickle cell disease and obstructive sleep apnea. (28078488)
2017
11
A Comment on Pattern of Opioid Use in Sickle Cell Disease. (28052380)
2017
12
AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain. (28065813)
2017
13
Genome-Wide Analysis Identifies IL-18 and FUCA2 as Novel Genes Associated with Diastolic Function in African Americans with Sickle Cell Disease. (27636371)
2016
14
Sickle cell disease severity: an introduction. (27190296)
2016
15
Correction: Emergency Department Visits and Inpatient Admissions Associated with Priapism among Males with Sickle Cell Disease in the United States, 2006-2010. (27557148)
2016
16
An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine. (27636225)
2016
17
Evidence of benefits from using fresh and cryopreserved blood to transfuse patients with acute sickle cell disease. (27184475)
2016
18
Oral health-related quality of life of children and teens with sickle cell disease. (27208568)
2016
19
Psychometric Validation of the Insomnia Severity Index in Adults with Sickle Cell Disease. (27217712)
2016
20
The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis. (27181705)
2016
21
Immunogenicity and Safety Of 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children with Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study. (28030521)
2016
22
A rapid, inexpensive and disposable point-of-care blood test for sickle cell disease using novel, highly specific monoclonal antibodies. (27605462)
2016
23
Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/I^-thalassemia patients. (26895070)
2016
24
Effect of Hereditary Hemochromatosis Gene (HFE) H63D and C282Y Mutations on Iron Overload in Sickle Cell Disease Patients. (27095682)
2016
25
Original Research: Acute chest syndrome in sickle cell disease: Effect of genotype and asthma. (26936083)
2016
26
Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. (28005272)
2016
27
Score Predicting Acute Chest Syndrome During Vaso-occlusive Crises in Adult Sickle-cell Disease Patients. (27412264)
2016
28
Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait. (27613177)
2016
29
Clinically-oriented proteomic investigation of sickle cell disease: Opportunities and challenges. (27193514)
2016
30
Emergency Department Visits and Inpatient Admissions Associated with Priapism among Males with Sickle Cell Disease in the United States, 2006-2010. (27078839)
2016
31
Can Preconsent Eliminate Some Barriers to Clinical Trial Enrollment of Children With Sickle Cell Disease in Crisis? (27189802)
2016
32
Hot Off the Press: Which Febrile Children With Sickle Cell Disease Need a Chest X-Ray? (28008687)
2016
33
Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and I^-thalassemia. (27601644)
2016
34
Alloimmunisation rates of sickle cell disease patients in the United States differ from those in other geographical regions. (27197689)
2016
35
Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. (27639254)
2016
36
Safety and feasibility of red cell exchange for sickle cell disease across Canada. (27179925)
2016
37
Hydroxyurea and Pain History in Relation to Patient-Reported Outcomes Using PROMIS Measures and the Frequency of Assessments in Sickle Cell Disease Patients. (27187560)
2016
38
Spectrum of kidney diseases in Africa: malaria, schistosomiasis, sickle cell disease, and toxins. (27509585)
2016
39
A case of delayed hemolytic transfusion reaction in sickle cell disease patient. (27605854)
2016
40
Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease. (26799428)
2016
41
Osteonecrosis in Sickle Cell Disease. (27598354)
2016
42
Hematopoietic stem cell transplantation for people with sickle cell disease. (27194464)
2016
43
Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease. (27643455)
2016
44
Blood transfusions for treating acute chest syndrome in people with sickle cell disease. (27574910)
2016
45
Anaesthetic challenges in a child with sickle-cell disease and congenital heart block. (27141119)
2016
46
Loss of Bone in Sickle Cell Trait and Sickle Cell Disease Female Mice Is Associated with Reduced IGF-1 in Bone and Serum. (27171384)
2016
47
Spleen histology in children with sickle cell disease and hereditary spherocytosis: Hints on the disease pathophysiology. (27771375)
2016
48
Health Resources and Services Administration's Efforts to Improve Sickle Cell Disease Care. (27598371)
2016
49
Effect of Free Dental Services on Individuals with Sickle Cell Disease. (27598367)
2016
50
Acute Chest Syndrome, Asthma, and Lung Function in Sickle Cell Disease. Which Is the Chicken, and Which Is the Egg? (27509149)
2016

Variations for Sickle Cell Disease

About this section

Clinvar genetic disease variations for Sickle Cell Disease:

5
id Gene Variation Type Significance SNP ID Assembly Location
1HBBNM_000518.4(HBB): c.20A> T (p.Glu7Val)SNV, HaplotypePathogenic, protectivers334GRCh37Chr 11, 5248232: 5248232

Expression for genes affiliated with Sickle Cell Disease

About this section
Search GEO for disease gene expression data for Sickle Cell Disease.

Pathways for genes affiliated with Sickle Cell Disease

About this section

Pathways related to Sickle Cell Disease according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.5HBA2, HBB, VCAM1
29.0HBB, HBD, HBG1, HBG2
38.6HBA2, HBB, SELP, VCAM1

GO Terms for genes affiliated with Sickle Cell Disease

About this section

Cellular components related to Sickle Cell Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1endocytic vesicle lumenGO:007168210.3HBA2, HBB
2haptoglobin-hemoglobin complexGO:003183810.2HBA2, HBB
3blood microparticleGO:00725629.4HBA2, HBB, HBD, HBG2
4hemoglobin complexGO:00058338.7HBA2, HBB, HBD, HBG1, HBG2

Biological processes related to Sickle Cell Disease according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1hydrogen peroxide catabolic processGO:004274410.6HBA2, HBB
2cell volume homeostasisGO:000688410.5KCNN4, SLC12A4
3erythrocyte maturationGO:004324910.4EPO, G6PD
4calcium-mediated signaling using intracellular calcium sourceGO:00355849.8SELP, VCAM1
5leukocyte cell-cell adhesionGO:00071599.8SELP, VCAM1
6leukocyte tethering or rollingGO:00509019.8SELP, VCAM1
7response to ethanolGO:00454719.8G6PD, UGT1A1, VCAM1
8blood coagulationGO:00075969.7HBB, HBD, HBG1, HBG2
9response to nutrientGO:00075849.6EPO, UGT1A1, VCAM1
10oxygen transportGO:00156719.4HBA2, HBB, HBD, HBG1, HBG2
11response to organic cyclic compoundGO:00140708.8G6PD, SELP, UGT1A1
12response to lipopolysaccharideGO:00324968.8EPO, SELP, UGT1A1, VCAM1

Molecular functions related to Sickle Cell Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1haptoglobin bindingGO:003172010.6HBA2, HBB
2peroxidase activityGO:000460110.0HBA2, HBB
3heme bindingGO:00200379.3HBA2, HBB, HBD, HBG1, HBG2
4iron ion bindingGO:00055069.3HBA2, HBB, HBD, HBG1, HBG2
5oxygen bindingGO:00198259.2HBA2, HBB, HBD, HBG1, HBG2
6oxygen transporter activityGO:00053449.1HBA2, HBB, HBD, HBG1, HBG2

Sources for Sickle Cell Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet